Skip to main content

BBS-Bioactive Bone Substitutes Plc: The CE marking application of the Company’s ARTEBONEⓇ Paste product is in progress

Written by Customer Service on . Posted in Public Companies.

BBS-Bioactive Bone Substitutes Plc has received an offer and a draft contract concerning handling of application for CE marking of ARTEBONEⓇ Paste product, company’s ISO 13485 certification and related audits from Notified Body BSI (the Netherlands).  The company has approved the offer and contract but the contract includes new requests of documents. The company is currently preparing these documents. Upon completion, the company is ready to submit technical documentation related to the application of CE marking to the Notified Body.
As part of the documentation to be submitted is the additional evidence of functionality of ARTEBONEⓇ Paste required by the authority. Preliminary reports from the first and second follow-up time points have been received from the results of an animal experiment commissioned by the company last autumn. The results of the third and at the same time the last time point are still expected. According to the company’s own opinion, the results are positive and they are capable of demonstrating the additional evidence.  A change is still being made to the original way of measuring results, which  will further refine the results already obtained.CEO Ilkka Kangasniemi:We are pleased that, in addition to dealing with the global corona pandemic, the authority has finally had time to respond to our call for tenders. Additionally, we are satisfied with the preliminary results of the animal experiment. After further measurements, the results are presumably valid to demonstrate the additional screen requirement that the authority has requested of us. For now, we are not changing the time table of the CE marking process. The possible effects of the additional document requirements and the specification of the method of measuring the results of the animal experiment on the schedule will be investigated and, if necessary, more information will be released during the autumn.BBS-BIOACTIVE BONE SUBSTITUTES PLCFor more information:CEO Ilkka KangasniemiPhone: +358 40 7080307E-mail: ilkka.kangasniemi@bbs-artebone.fiThis is information that BBS-Bioactive Bone Substitutes Plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on 7 August 2020 at 12:00 am (UTC +3.00).About BBSBBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech company. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things.  We have over 20 years of expertise in this. Our operations are characterised by top expertise, innovativeness and dedicated and committed employees. The first product, ARTEBONE® paste, is ready and the application process for the CE-marking enabling commercialization is in progress.More information: www.bbs-artebone.fi.BBS-Bioactive Bone Substitutes Plc shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. The company’s Certified Adviser is Stockholm Certified Advisers AB, p. +46 70 5516 729, info@certifiedadviser.se

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.